Document Detail

Immunomodulation with human recombinant autoantigens.
MedLine Citation:
PMID:  16153889     Owner:  NLM     Status:  MEDLINE    
The loss of beta cells in type 1 diabetes is the consequence of a T cell-dependent autoimmune attack. Autoantibodies against GAD65 (Mr 65.000 isoform of glutamic acid decarboxylase), IA-2 (insulinoma-associated protein IA-2) or insulin, alone or in combination, predict disease. Preclinical studies in spontaneously diabetic rodents suggest that immunomodulation with autoantigens might alter the course of autoimmune diabetes. Oral insulin reduces the development of diabetes in risk subjects with high insulin autoantibody levels. Giving alum-formulated GAD65 to patients classified with latent autoimmune diabetes of the adult (LADA) is safe and suggests possible immunomodulating effects of GAD65. Future immunomodulation trials might better ascertain subjects based on HLA genetic risk factors, the level of insulin that is still produced or by combining autoantigens with, for example, anti-CD3 antibodies, to induce antigen-specific tolerance and thereby a long-lasting protection for beta cells.
Ake Lernmark; Carl-David Agardh
Related Documents :
8167389 - False-positive treponemal serology in patients with diabetes mellitus.
12593469 - C-peptide and autoimmune markers in diabetes.
17074529 - Apoptosis in the pathophysiology of diabetes mellitus.
8904929 - Soluble cd8 antigen, stimulated c-peptide and islet cell antibodies are predictors of i...
1865079 - Islet cell surface antibodies by an elisa method in diabetic and nondiabetic patients.
11460579 - Modern concepts for the prediction of type 1 diabetes.
2849069 - Decreased central gaba b receptor binding sites in diabetic rats.
1267549 - Diabetes among men in a general population. prevalence and associated physiological fin...
21093089 - A novel dipeptidyl peptidase iv inhibitor da-1229 ameliorates streptozotocin-induced di...
Publication Detail:
Type:  Journal Article; Review     Date:  2005-09-08
Journal Detail:
Title:  Trends in immunology     Volume:  26     ISSN:  1471-4906     ISO Abbreviation:  Trends Immunol.     Publication Date:  2005 Nov 
Date Detail:
Created Date:  2005-10-21     Completed Date:  2006-03-09     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  100966032     Medline TA:  Trends Immunol     Country:  England    
Other Details:
Languages:  eng     Pagination:  608-12     Citation Subset:  IM    
The University of Washington, Department of Medicine, Seattle, WA 981905, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Autoantibodies / immunology
Autoantigens / immunology*
Diabetes Mellitus, Type 1 / drug therapy,  immunology*
Glutamate Decarboxylase / immunology
Immunologic Factors / immunology*
Insulin / immunology,  therapeutic use
Isoenzymes / immunology
Membrane Proteins / immunology
Protein Tyrosine Phosphatase, Non-Receptor Type 1
Protein Tyrosine Phosphatases / immunology
Receptor-Like Protein Tyrosine Phosphatases, Class 8
Recombinant Proteins / immunology
Reg. No./Substance:
0/Autoantibodies; 0/Autoantigens; 0/Immunologic Factors; 0/Isoenzymes; 0/Membrane Proteins; 0/Recombinant Proteins; 11061-68-0/Insulin; EC protein, human; EC Tyrosine Phosphatase, Non-Receptor Type 1; EC Tyrosine Phosphatases; EC Protein Tyrosine Phosphatases, Class 8; EC Decarboxylase; EC decarboxylase 2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Regulation of intermediary metabolism in rat cardiac myocyte by extracellular glycerol.
Next Document:  SLE: translating lessons from model systems to human disease.